Söndag 22 December | 07:46:23 Europe / Stockholm
Svenska | English

Pharma Equity Group

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (DKK).

Likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-06-03 - Extra Bolagsstämma 2024
2024-05-16 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning PEG 0.00 DKK
2024-04-16 - Årsstämma
2024-03-20 - Bokslutskommuniké 2023
2023-11-02 - Extra Bolagsstämma 2023
2023-08-16 - Kvartalsrapport 2023-Q2
2023-04-26 - X-dag ordinarie utdelning PEG 0.00 DKK
2023-04-25 - Årsstämma
2023-03-31 - Bokslutskommuniké 2022
2022-10-27 - Extra Bolagsstämma 2022
2022-08-31 - Kvartalsrapport 2022-Q2
2022-04-26 - X-dag ordinarie utdelning PEG 0.00 DKK
2022-04-25 - Årsstämma
2022-03-31 - Bokslutskommuniké 2021
2022-01-21 - Bokslutskommuniké 2021
2021-11-10 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-05-03 - X-dag ordinarie utdelning PEG 0.00 DKK
2021-04-29 - Årsstämma
2020-08-24 - Kvartalsrapport 2020-Q2
2020-04-28 - X-dag ordinarie utdelning PEG 0.00 DKK
2020-04-27 - Årsstämma
2020-03-30 - Bokslutskommuniké 2019
2019-11-01 - Split PEG 10:1
2019-08-23 - Kvartalsrapport 2019-Q2
2019-04-29 - X-dag ordinarie utdelning PEG 0.00 DKK
2019-04-26 - Årsstämma
2019-03-29 - Bokslutskommuniké 2018
2019-02-26 - Extra Bolagsstämma 2019
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2018-04-30 - Årsstämma
2018-04-06 - Bokslutskommuniké 2017
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2017-04-28 - Årsstämma
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-05-02 - X-dag ordinarie utdelning PEG 0.00 DKK
2016-04-29 - Årsstämma
2016-03-31 - Bokslutskommuniké 2015
2016-02-24 - Split PEG 1:10
2016-02-18 - Extra Bolagsstämma 2016
2015-10-21 - Kvartalsrapport 2015-Q3
2015-07-15 - Kvartalsrapport 2015-Q2
2015-05-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2015-04-30 - Årsstämma
2015-04-14 - Kvartalsrapport 2015-Q1
2015-03-31 - Bokslutskommuniké 2014
2015-02-02 - Extra Bolagsstämma 2015
2014-12-22 - Extra Bolagsstämma 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-15 - Kvartalsrapport 2014-Q2
2014-05-09 - Kvartalsrapport 2014-Q1
2014-04-30 - Årsstämma
2014-04-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2014-03-31 - Bokslutskommuniké 2013
2013-11-06 - Kvartalsrapport 2013-Q3
2013-08-16 - Kvartalsrapport 2013-Q2
2013-05-07 - Kvartalsrapport 2013-Q1
2013-04-30 - Årsstämma
2013-04-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2013-03-29 - Bokslutskommuniké 2012
2012-11-06 - Kvartalsrapport 2012-Q3
2012-08-17 - Kvartalsrapport 2012-Q2
2012-05-07 - Kvartalsrapport 2012-Q1
2012-05-01 - X-dag ordinarie utdelning PEG 0.00 DKK
2012-04-30 - Årsstämma
2012-03-30 - Bokslutskommuniké 2011
2011-11-04 - Extra Bolagsstämma 2011
2011-05-02 - X-dag ordinarie utdelning PEG 0.00 DKK
2011-04-29 - Årsstämma
2010-05-03 - X-dag ordinarie utdelning PEG 0.00 DKK

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Pharma Equity Group utvecklar nya läkemedel för lokal behandling av allvarliga och livshotande inflammatoriska sjukdomar för vilka det för närvarande inte finns någon adekvat behandling. Bolaget använder ompositionering av befintliga läkemedel och tar läkemedelskandidater till ett kliniskt fas III-stadium, varefter de överlämnas till en strategisk partner som kommer att slutföra utvecklingen av produkterna och föra ut dem på marknaden, antingen självständigt eller i samarbete med bolaget.
Passing of the General Meeting of Pharma Equity Group A/S
2024-04-16 17:29:23
  
  
 Passing of the General Meeting of Pharma Equity Group A/S
  

16 April 2024
Company Announcement no. 13

 
Pharma Equity Group A/S today held its Annual General Meeting with the following results:

1) The board of directors' report on the Company's activities in the past year was noted by the General Meeting

2) The audited annual report was approved

3) The executive board and the board of directors was discharged from liability

4) Appropriation of profit or loss as proposed by the board of directors was adopted

5) The remuneration report 2023 for an advisory vote was approved

6) The remuneration to the board of directors for the current financial year was approved

  • The chair of the board of directors receives DKK 350,000.
  • The deputy chair of the board of directors receives DKK 250,000.
  • Members of the board of directors receive DKK 150,000.



  • Members of the board of directors' audit committee, the nomination- and remuneration committee or other committees receive a remuneration of DKK 25,000 in total for all committee work. This does not apply to the chair or the deputy chair of the board of directors, who does not receive additional remuneration.
 7) Election of the board of directors
 

The following board members was re-elected: Christian Vinding Thomsen, Martin Engell-Rossen, Omar S. Qandeel, Lars Gundorph and Peter Vilmann.

 
The board constituted itself the following way after the General Meeting: Christian Vinding Thomsen (chair), Martin Engell-Rossen (deputy chair), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.

 
8) BDO STATSAUTORISERET REVISIONSAKTIESELSKAB (“BDO”), Havneholmen 29, 1561 København V, CVR no. 20222670 was elected as the Company’s auditor.

9) The following proposals from the board of directors were approved:

  1. Proposal to increase the authorization to issue new shares with pre-emption rights (article 4.1.A)
  2. Proposal to combine and increase the two separate authorizations to issue new shares without pre-emption rights and grant a one-year extension of the new combined authorization (articles 4.1.B and 4.1.C)
  3. Proposal to grant a one-year extension of the authorization to issue warrants (article 4.2)
  4. Proposal to increase the authorization to issue convertible loan notes (article 4.3.A)
10) The chair of the general meeting, with a right of substitution, was authorized to file the resolutions adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require in order to register or approve the resolutions adopted. 

For further information, please contact:

 
 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
  

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

 

 

Attachments

2024 04 16 - Announcement no. 13 - UK

Källa GlobeNewswire Nordic
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden